-
-
-
-
-
-
-
Cogent Biosciences outlines 2026 milestones for bezuclastinib drug applications
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Cogent (COGT)
-
-
-
-
-
-
-
Cogent (COGT) PT Raised to $50 at Leerink Partners
-
-
-
-
-
-
-
Stifel Starts Cogent (COGT) at Hold
-
-
-
-
-
-
-
Cogent (COGT) PT Raised to $22 at Citi, Removes 30d Upside Catalyst Watch
-
-
-
-
-
-
-
Cogent Biosciences (COGT) reports positive results from mastocytosis drug trial
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Cogent (COGT)
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

